000075 SSE Health Care Sector Equal Weight Index
- 6220.57
- +35.42+0.57%
Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.
Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
2024 Financial Report | Insulin Low Price Competition, Gan Li Pharmaceutical's Gains and Losses
Go out to sea
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
Pharmacovigilance disintegrates CXO, what is the market concerned about?
It was only in December that the full-year forecast was lowered. What kind of medicine does Yakumin Biotech sell in gourds?
WuXi AppTec GAAP EPS of RMB 0.94, Revenue of RMB 10.67B
“Yemao” Tongze Healthcare's revenue growth in the third quarter was close to stagnation, and net profit fell 5.58% year on year | Financial News
Tongce Medical's revenue for the first three quarters was 2.85 billion yuan, up 2.12% year on year; net profit to mother was 512 million yuan, a decrease of 0.67% year on year.
There are not enough diet pills, Pharmacom announces another 60% increase in production capacity | Insight Research
Pharmaceutical Kangde announced today that its subsidiary Hequan Pharmaceutical will increase its peptide production capacity by 60%. At present, Hequan Pharmaceutical has begun a polypeptide production capacity expansion project for two production sites in Changzhou and Taixing. After the expansion is completed, Hequan Pharmaceutical will add multiple solid phase synthesis production lines for peptides. The new production capacity is expected to be put into use in December 2023. At that time, the volume of the peptide solid phase synthesis reactor will increase from the 20,000L originally planned to 32,000L. Previously, at the production site of Pharmaceutical Ming Kangde in Changzhou, WuXiTides put into operation two 2,000L polypeptide solid-phase synthesizers in April of this year, which means WuXiti
Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist
In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons
Shanghai Fosun Pharmaceutical Reports 1H Results
WuXi AppTec Reports Q2 Results
2023 Interim Report | When CT Is No Longer a “Amulet”: What is Lianying Healthcare's MR Growth Space
Also watch This Morning
2023 Interim Report | Aibo Medical is increasing optometry and evasion and wants to launch the GDR to hit overseas markets?
Lustful and honest
It soared by 120 billion US dollars overnight! Eli Lilly vs. Novo Nordisk, the battle for diet pills begins
It is only a matter of time before K drugs become the next generation medicine king. It is only a matter of time before they become the magic medicine for weight loss.
Yao Ming Kant “Cheer” on the Magic Medicine Express for Weight Loss | Insightful Research
CXO may not be as pessimistic as market expectations. On July 31, at a time when the entire pharmaceutical sector was being drastically adjusted, the CXO sector bucked the trend and rose throughout the day due to Kanglong Chemical's performance forecast. On the evening of the same day, Yao Ming Kangde released its 2023 semi-annual report, which seemed to give the CXO industry a little more confidence. CXO's leading performance was strong. Excluding COVID-19, 2023H1 is still growing fast. Pharmacomingkang's revenue was 18.871 billion yuan, up 6.3% year on year, excluding COVID-19 commercialization projects, up 27.9% year on year; net profit for the first half of the year was 5.313 billion yuan, up 14.6% year on year; adjusted N in the first half of the year
WuXi AppTec GAAP EPS of $1.07, Revenue of $9.91B Beats by $8.57B
Zhaoyan's new drug to “hoard monkeys roll over” has come to a standstill
The fried monkey rolled over. Recently, the 2023 semi-annual report of Zhaoyan New Drug (603127.SH) predicted a sharp decline in net profit. According to the performance forecast, the net profit of Zhaoyan New Drug in the first half of 2023 is expected to be 73 million yuan to 110 million yuan, with a year-on-year decline range of 70.40% to 80.40%. Excluding the net profit of 188 million yuan in the first quarter of 2023, Zhaoyan New Pharmaceutical already lost money in the second quarter, only about -115 million yuan to -078 million yuan. However, at the same time, there was no sharp decline in revenue from Zhaoyan New Pharmaceuticals. In the first half of 2023